Latest Conference Articles

October 20th 2017, 12:51am

SMR Congress

While chemotherapy has historically been used to treat patients with Merkel cell carcinoma, immunotherapy advances have infused new hope into the treatment landscape.

October 19th 2017, 6:57pm

SMR Congress

Jason Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the combination approach of a PD-1 antibody plus an IDO inhibitor for patients with melanoma.

October 19th 2017, 5:25pm

SMR Congress

Alan Shain, PhD, postdoctoral scholar, UCSF School of Medicine, discusses the role of genetics in melanoma.

October 19th 2017, 5:19pm

SMR Congress

Adil Daud, MD, clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses challenges facing the treatment landscape of melanoma.

October 19th 2017, 1:10am

IASLC World Conference on Lung Cancer

Marina Chiara Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses some of the recent exciting results regarding immunotherapy in non-small cell lung cancer (NSCLC).

October 19th 2017, 12:47am

IASLC World Conference on Lung Cancer

Two-year results showed that frontline pembrolizumab (Keytruda) more than doubled median overall survival compared with standard chemotherapy in patients with high PD-L1 expressing non–small cell lung cancer

October 19th 2017, 12:17am

IASLC World Conference on Lung Cancer

Ado-trastuzumab emtansine (Kadcyla) is active and well tolerated in patients with advanced HER2-mutant or amplified lung cancers as identified by next generation sequencing.

October 19th 2017, 12:13am

IASLC World Conference on Lung Cancer

Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses the significance of the results of a trial exploring entrectinib in patients with ROS1-positive non

October 18th 2017, 8:00pm

IASLC World Conference on Lung Cancer

Treatment with entrectinib induced an objective response rate of 68.8% by blinded independent central review, which included 2 complete responses (6.3%), for patients with ROS1 fusion-positive advanced non–small cell lung cancer.

October 18th 2017, 6:48pm

SMR Congress

The use of intralesional therapies in combination with checkpoint inhibitors has shown to be an improvement to monotherapy and combinations with immunotherapy in melanoma.

October 18th 2017, 5:56pm

IASLC World Conference on Lung Cancer

The potent small molecule TKI ensartinib has shown promise and meaningful intercranial activity in ALK-positive, TKI-naïve patients with non–small cell lung cancer.

October 18th 2017, 2:21am

IASLC World Conference on Lung Cancer

Lorlatinib induced an objective response rate of 90% in treatment-naïve patients with ALK-positive non–small cell lung cancer.

October 18th 2017, 12:51am

IASLC World Conference on Lung Cancer

Patient reported outcomes from the PACIFIC trial of durvalumab versus placebo after chemoradiation in locally advanced unresectable NSCLC show that durvalumab had no serious impact on quality of life.

October 18th 2017, 12:03am

IASLC World Conference on Lung Cancer

There was a high concordance between central tissue and plasma circulating tumor DNA testing for EGFR mutations in patients enrolled in the phase III FLAURA study of frontline osimertinib (Tagrisso) in NSCLC.

October 17th 2017, 11:27pm

IASLC World Conference on Lung Cancer

Geoffrey R. Oxnard, MD, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses resistance mechanisms that occur in patients with EGFR-positive T790M non

October 17th 2017, 11:15pm

IASLC World Conference on Lung Cancer

The combination of osimertinib and the MET inhibitor savolitinib showed signs of efficacy for pretreated patients with MET-positive, EGFR-mutant non–small cell lung cancer.

October 17th 2017, 11:02pm

IASLC World Conference on Lung Cancer

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a study exploring entrectinib in patients with ROS1-positive, advanced or metastatic non-small cell lung cancer (NSCLC) during an interview at the IASLC 18th World Conference on Lung Cancer in Yokohama, Japan.

October 17th 2017, 7:53pm

IASLC World Conference on Lung Cancer

Second-generation EGFR inhibitor dacomitinib showed clear superiority over first-generation TKI gefitinib (Iressa) in a comparison of performance in EGFR mutation subtypes exon 19 deletion and L858R in advanced NSCLC.

October 17th 2017, 6:34pm

IASLC World Conference on Lung Cancer

Ramucirumab (Cyramza) plus docetaxel demonstrated an overall survival benefit versus placebo plus docetaxel in patients with advanced NSCLC whose disease rapidly progressed on first-line therapy,

October 16th 2017, 11:39pm

IASLC World Conference on Lung Cancer

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, discusses the significance of the phase III FLAURA trial of first-line osimertinib (Tagrisso) in EGFR-mutant non-small cell lung cancer (NSCLC).